510(k) Report

510(k) · Cleared

Cleared

Regulora

K211463510(k) TraditionalCleared Nov 24, 2021197-day reviewClass II21 CFR 876.5960

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Metame Health, Inc. · QMY Computerized Behavioral Therapy Device For Treating Symptoms

Cleared on Nov 24, 2021 as substantially equivalent to DEN200029 (Mahana Therapeutics, Inc., 2020) after a 197-day review. Its family tree reaches back 1 generation to 2020.

Decided
Nov 24, 2021
Review
197 days
Class
Class II
Product code
QMY
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to DEN200029 (2020). No later device cites it as a predicate yet.

DEN200029 · Parallel · Mahana Therapeutics, Inc. · 202020202022
DEN200029 · Parallel · Mahana Therapeutics, Inc. · 20200
  1. Root · 1 generation backDEN200029 ParallelMahana Therapeutics, Inc. · 2020
  2. This deviceK211463 ReguloraMetame Health, Inc. · 2021
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1DEN200029ParallelMahana Therapeutics, Inc.2020—
0 (this device)K211463ReguloraMetame Health, Inc.2021—
FIG. 1 — Lineage of K211463, 2020–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QMY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QMY device

  1. #1 K211372 Mahana Parallel Digital Cognitive Behavioral…score 1.5 · 1 generation · no Class I recall
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*DEN200029Parallel
Summary page 4
…Classification Name: Computerized behavioral therapy device for treating symptoms Predicate Device: Parallel, DEN200029 Device Description Regulora™ is prescription-only digital therapeutic software indicated for use in the treatment of abdominal p…
Mahana Therapeutics, Inc.2020—

Also cleared against DEN200029: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.
  • 1 other device also cites its predicate DEN200029.

How does its category compare?

All QMY devices

QMY Computerized Behavioral Therapy Device For Treating Symptoms: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · QMY

2in 2021

2020: 12021: 2
2007high 2 (2021) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QMY

Too few QMY 510(k)s in any year since 2007 to give a median.

Recalls per year · QMY

No recall names QMY since 2007.

Adverse event reports per year · QMY

No MAUDE report names QMY since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20201—00
20212—00
20220—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

Regulora™ is a prescription-only digital therapeutic device intended to provide behavioral therapy through gut-directed hypnotherapy for adults 22 years of age and older who have been diagnosed with Irritable Bowel Syndrome (IBS). Regulora is indicated as a 3-month treatment for patients with abdominal pain due to IBS and is intended to be used together with other IBS treatments.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K211463: Regulora.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K211463

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026